Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia最新文献_第9页

The role of viral diagnostic tests in respiratory tract infections: moving forward. 病毒诊断测试在呼吸道感染中的作用：向前迈进。

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-04-12 DOI: 10.37201/req/150.2023

Raúl Ortíz de Lejarazu, J. Eiros, F. López‐Medrano, Milagros Montes, Alfredo Tagarro, María Tomás

{"title":"The role of viral diagnostic tests in respiratory tract infections: moving forward.","authors":"Raúl Ortíz de Lejarazu, J. Eiros, F. López‐Medrano, Milagros Montes, Alfredo Tagarro, María Tomás","doi":"10.37201/req/150.2023","DOIUrl":"https://doi.org/10.37201/req/150.2023","url":null,"abstract":"The increased knowledge on virology and the increased potential of their diagnostic has risen several relevant question about the role of an early viral diagnosis and potential early treatment on the management of respiratory tract infections (RTI). In order to further understand the role of viral diagnostic tests in the management of RTI, a panel of experts was convened to discuss about their potential role, beyond what had been agreed in Influenza. The objective of this panel was to define the plausible role of aetiologic viral diagnostic into clinical management; make recommendations on the potential expanded use of such tests in the future and define some gaps in the management of RTI. Molecular Infection Viral Diagnostic (mIVD) tests should be used in all adult patients admitted to Hospital with RTI, and in paediatric patients requiring admission or who would be referred to another hospital for more specialised care. The increased use of mIVD will not only reduce the inappropriate use of antibiotics so reducing the antibiotic microbe resistance, but also will improve the outcome of the patient if an aetiologic viral therapy can be warranted, saving resource requirements and improving patient flows. Implementing IVD testing in RTI has various organizational benefits as well, but expanding its use into clinical settings would need a cost-effectiveness strategy and budget impact assessment.","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":"21 33","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140711581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biofilm prevention concentration of clarithromycin against clinically relevant species of nontuberculous mycobacteria. 克拉霉素对非结核分枝杆菌临床相关菌种的生物膜预防浓度。

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-04-11 DOI: 10.37201/req/014.2024

Abrar Senhaji-Kacha, Arij Akir, Antonio Broncano-Lavado, Jaime Esteban

{"title":"Biofilm prevention concentration of clarithromycin against clinically relevant species of nontuberculous mycobacteria.","authors":"Abrar Senhaji-Kacha, Arij Akir, Antonio Broncano-Lavado, Jaime Esteban","doi":"10.37201/req/014.2024","DOIUrl":"https://doi.org/10.37201/req/014.2024","url":null,"abstract":"OBJECTIVE\u0000Mycobacterium avium complex (MAC) and Mycobacterium abscessus are a group of nontuberculous mycobacteria (NTM) that have been described as human pathogens. Their ability to develop biofilms in tissues and medical devices is one of the most important pathogenicity factors, with important implications in diagnosis and treatment. Macrolides are usually considered one of the bases of this treatment.\u0000\u0000\u0000METHODS\u0000Here we have studied the biofilm prevention concentration (BPC) of 16 strains (n=16) with clarithromycin to avoid the biofilm development by these NTM.\u0000\u0000\u0000RESULTS\u0000In this study, all M. abscessus strains have similar BPC, while MAC strains showed different values. For MAC the concentrations ranged between 1-16 mg/L, while for M. abscessus the concentration was 32 mg/L for all strains except one that was 64 mg/L.\u0000\u0000\u0000CONCLUSIONS\u0000These results open the possibility of using macrolides for the prevention of biofilm development in patients with a risk of developing NTM disease.","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":"39 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140713846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Infective endocarditis due to Listeria monocytogenes: Case treated without surgical intervention with adequate clinical evolution]. [李斯特菌引起的感染性心内膜炎：无需手术治疗的病例，临床症状得到充分改善]。

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-04-10 DOI: 10.37201/req/141.2023

Telmo Fernandez de Casadevante, Xabier Camino, Ainhoa Arteche, Ana Alonso, Paul Martinage

引用次数: 0

Azithromycin and moxifloxacin resistance determinants in Mycoplasma genitalium in Lleida, Spain. 西班牙莱里达地区生殖支原体对阿奇霉素和莫西沙星的耐药性决定因素。

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-04-09 DOI: 10.37201/req/015.2024

Lucía Fraile García, J. Aramburu Arnuelos, Éric López González, Alba Bellés-Bellés, A. Muñoz Santa, Elena Sánchez Báscones, S. Mormeneo Bayo, A. Bernet Sánchez, I. Prats Sánchez, Alejandro Cumplido Portillo,, Mercè García González

{"title":"Azithromycin and moxifloxacin resistance determinants in Mycoplasma genitalium in Lleida, Spain.","authors":"Lucía Fraile García, J. Aramburu Arnuelos, Éric López González, Alba Bellés-Bellés, A. Muñoz Santa, Elena Sánchez Báscones, S. Mormeneo Bayo, A. Bernet Sánchez, I. Prats Sánchez, Alejandro Cumplido Portillo,, Mercè García González","doi":"10.37201/req/015.2024","DOIUrl":"https://doi.org/10.37201/req/015.2024","url":null,"abstract":"OBJECTIVE\u0000Mycoplasma genitalium (MG) is a microorganism related to sexually transmitted infections. Antibiotic resistance of MG leads to an increase in treatment failure rates and the persistence of the infection. The aim of this study was to describe the most frequent mutations associated with azithromycin and moxifloxacin resistance in our geographical area.\u0000\u0000\u0000METHODS\u0000A prospective study from May 2019 to May 2023 was performed. MG-positive samples were collected. Real-time PCRs (AllplexTM MG-AziR Assay and AllplexTM MG-MoxiR Assay, Seegene) were performed in MG positive samples to detect mutations in 23S rRNA V domain and parC gene.\u0000\u0000\u0000RESULTS\u0000A 37.1% of samples presented resistance determinants to azithromycin and the most common mutation detected was A2059G (57.9%). Resistance to moxifloxacin was studied in 72 azithromycin-resistant samples and 36.1% showed mutations, being G248T the most prevalent (73.1%).\u0000\u0000\u0000CONCLUSIONS\u0000The resistance to different lines of treat ment suggests the need for a targeted therapy and the performing of a test of cure afterwards.","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":"10 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140725435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Disseminated nocardiosis]. [播散性球虫病]。

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-04-01 Epub Date: 2024-01-30 DOI: 10.37201/req/119.2023

L R Iotti, M de Frutos, B Lorenzo-Vidal, J M Eiros

引用次数: 0

[Penetration in cerebrospinal fluid and use of ceftaroline in ventriculitis associated with external ventricular drainage]. [脑脊液渗透和头孢他啶在伴有脑室外引流的脑室炎中的应用]。

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-04-01 Epub Date: 2024-02-13 DOI: 10.37201/req/131.2023

I Ramos, A Benítez-Cano, S Luque, L Sorlí, R Adalia

引用次数: 0

An unexpected pathogen in the amniotic fluid of a patient with chorioamnionitis. 绒毛膜羊膜炎患者羊水中的意外病原体。

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-04-01 Epub Date: 2024-02-13 DOI: 10.37201/req/132.2023

E Rubio-Mora, J Cacho-Calvo, I Quiles Melero

引用次数: 0

Efficacy of delafloxacin alone and in combination with cefotaxime against cefotaxime non-susceptible invasive isolates of Streptococcus pneumoniae. 地拉沙星单独使用和与头孢他啶联合使用对头孢他啶不敏感的肺炎链球菌侵袭性分离株的疗效。

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-04-01 Epub Date: 2024-01-16 DOI: 10.37201/req/107.2023

E Ríos, M Pérez, J C Sanz, A Delgado-Iribarren, I Rodríguez-Avial

{"title":"Efficacy of delafloxacin alone and in combination with cefotaxime against cefotaxime non-susceptible invasive isolates of Streptococcus pneumoniae.","authors":"E Ríos, M Pérez, J C Sanz, A Delgado-Iribarren, I Rodríguez-Avial","doi":"10.37201/req/107.2023","DOIUrl":"10.37201/req/107.2023","url":null,"abstract":"Objective: We assessed the in vitro activity of delafloxacin and the synergy between cefotaxime and delafloxacin among cefotaxime non-susceptible invasive isolates of Streptococcus pneumoniae (CNSSP).Methods: A total of 30 CNSSP (cefotaxime MIC > 0.5 mg/L) were studied. Serotyping was performed by the Pneumotest-Latex and Quellung reaction. Minimum inhibitory concentrations (MICs) of delafloxacin, levofloxacin, penicillin, cefotaxime, erythromycin and vancomycin were determined by gradient diffusion strips (GDS). Synergistic activity of delafloxacin plus cefotaxime against clinical S. pneumoniae isolates was evaluated by the GDS cross method.Results: Delafloxacin showed a higher pneumococcal activity than its comparator levofloxacin (MIC50, 0.004 versus 0.75 mg/L and MIC90, 0.047 versus >32 mg/L). Resistance to delafloxacin was identified in 7/30 (23.3%) isolates, belonging to serotypes 14 and 9V. Synergy between delafloxacin and cefotaxime was detected in 2 strains (serotypes 19A and 9V). Antagonism was not observed. Addition of delafloxacin increased the activity of cefotaxime in all isolates. Delafloxacin susceptibility was restored in 5/7 (71.4%) strains.Conclusions: CNSSP showed a susceptibility to delafloxacin of 76.7%. Synergistic interactions between delafloxacin and cefotaxime were observed in vitro among CNSSP by GDS cross method.","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"158-162"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10945109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139473133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Respiratory syncytial virus: A new era. 呼吸道合胞病毒：新时代。

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-04-01 Epub Date: 2024-01-11 DOI: 10.37201/req/147.2023

J Ruiz-Galiana, R Cantón, P De Lucas Ramos, A García-Botella, A García-Lledó, T Hernández-Sampelayo, J Gómez-Pavón, J González Del Castillo, M C Martín-Delgado, F J Martín Sánchez, M Martínez-Sellés, J M Molero García, S Moreno Guillén, F J Rodríguez-Artalejo, R Rodríguez Fernandez, M Kestler, E Bouza

{"title":"Respiratory syncytial virus: A new era.","authors":"J Ruiz-Galiana, R Cantón, P De Lucas Ramos, A García-Botella, A García-Lledó, T Hernández-Sampelayo, J Gómez-Pavón, J González Del Castillo, M C Martín-Delgado, F J Martín Sánchez, M Martínez-Sellés, J M Molero García, S Moreno Guillén, F J Rodríguez-Artalejo, R Rodríguez Fernandez, M Kestler, E Bouza","doi":"10.37201/req/147.2023","DOIUrl":"10.37201/req/147.2023","url":null,"abstract":"Respiratory syncytial virus (RSV) is a major public health problem that has undergone significant changes in recent years. First of all, it has become easier to diagnose with highly reliable and rapidly available confirmatory tests. This has led to a better understanding of its epidemiology and RSV has gone from being a disease of the pediatric age group, severe only in infants and immunosuppressed children, to being a common disease in people of all ages, particularly important in patients of advanced age or with immunosuppressive diseases. Recent therapeutic and prophylactic advances, both with long-lasting monoclonal antibodies and vaccines, are another reason for satisfaction. For these reasons, the COVID and Emerging Pathogens Committee of the Illustrious Official College of Physicians of Madrid (ICOMEM) has considered it pertinent to review this subject in the light of new knowledge and new resources for dealing with this infection. We have formulated a series of questions that we believe will be of interest not only to members of the College but also to any non-expert in this subject, with a particular focus on the situation of RSV infection in Spain.","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"134-148"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10945101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139418871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Secondary lumbosacral echinococcosis as presumptive sequelae of other primary locationses. 继发性腰骶部棘球蚴病是其他原发部位的假定后遗症。

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-04-01 Epub Date: 2024-02-23 DOI: 10.37201/req/148.2023

D Fernández Vecilla, M P Roche Matheus, M C Nieto Toboso, R Mongil Escudero, V Miguel Martínez, I Lombide Aguirre, J M Baraia-Etxaburu Artetxe, F Díez Renovales, J Rosselló Soria, J L Díaz de Tuesta Del Arco

引用次数: 0